Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

New innovations designed to simplify NGS workflows Enhances critical variant identification through improved ...

The key opportunities in the Global Personalized Medicine Biomarkers Market include advancements in genomic sequencing, growing reliance on targeted therapies, rising cancer and chronic disease ...

The Companion Diagnostics Market has emerged as a critical pillar of modern precision medicine, enabling healthcare providers ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

This article explores how tissue-based companion diagnostics leveraging immunohistochemistry approaches will help to select patients for targeted cancer treatments.

Targeted therapies are indicated for patients with non–small cell lung cancer (NSCLC) and driver tumor mutations. However, real-world studies on the survival benefits of these agents are limited. This ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive prostate cancer and personalise screening strategies.